A next-generation BRAF inhibitor overcomes resistance to BRAF inhibition in patients with BRAF-mutant cancers using pharmacokinetics-informed dose escalation

• Published in: Cancer discovery Vol. 14; no. 9; pp. 1599 - 1611
• Main Authors: Yaeger, Rona, McKean, Meredith A, Haq, Rizwan, Beck, J Thaddeus, Taylor, Matthew H, Cohen, Jonathan Eliezer, Bowles, Daniel W, Gadgeel, Shirish M, Mihalcioiu, Catalin, Papadopoulos, Kyriakos P, Diamond, Eli L, Sturtz, Keren B, Feng, Gang, Drescher, Stefanie K, Reddy, Micaela B, Sengupta, Bhaswati, Maity, Arnab K, Brown, Suzy A, Singh, Anurag, Brown, Eric N, Baer, Brian R, Wong, Jim, Mou, Tung-Chung, Wu, Wen-I, Kahn, Dean R, Gadal, Sunyana, Rosen, Neal, Gaudino, John J, Lee, Patrice A, Hartley, Dylan P, Rothenberg, S Michael
• Format: Journal Article
• Language: English
• Published: United States American Association for Cancer Research 04.09.2024
• Subjects: Cell Signaling; Research Briefs
• ISSN: 2159-8274; 2159-8290; 2159-8290
• DOI: 10.1158/2159-8290.CD-24-0024

RAF inhibitors have transformed treatment for BRAF V600-mutant cancer patients, but clinical benefit is limited by adaptive induction of ERK signaling, genetic alterations that induce BRAF V600 dimerization, and poor brain penetration. Next-generation pan-RAF dimer inhibitors are limited by narrow therapeutic index. PF-07799933 (ARRY-440) is a brain-penetrant, selective, pan-mutant BRAF inhibitor. PF-07799933 inhibited signaling in vitro, disrupted endogenous mutant-BRAF:wild-type-CRAF dimers, and spared wild-type ERK signaling. PF-07799933 ± binimetinib inhibited growth of mouse xenograft tumors driven by mutant BRAF that functions as dimers and by BRAF V600E with acquired resistance to current RAF inhibitors. We treated patients with treatment-refractory BRAF-mutant solid tumors in a first-in-human clinical trial (NCT05355701) that utilized a novel, flexible, pharmacokinetics-informed dose escalation design that allowed rapid achievement of PF-07799933 efficacious concentrations. PF-07799933 ± binimetinib was well-tolerated and resulted in multiple confirmed responses, systemically and in the brain, in BRAF-mutant cancer patients refractory to approved RAF inhibitors.